ZVRA
Zevra Therapeutics, Inc.
ZVRA's fundamentals are strong: revenue grew 75% and its operating margin went from −104% to 61%. At 9.2x earnings, it's trading below its usual 11x. Analysts expect that strong growth to continue, though they disagree widely on how much.
ZVRA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ZVRA's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZVRA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.4x | $7.75 | -31% |
| Current | 9.2x | $11.16 | — |
| Fair | 11x | $13.47 | +21% |
| Forward | 14x | $11.16 | — |
| Expensive | 24x | $28.69 | +157% |
Historical ranges are pointers, not guarantees.
ZVRA's PE is in its fair range at 9.2x. On analysts' estimates for next year's earnings, today's price would be 14x, in its expensive range.
ZVRA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ZVRA, with profitability improving. However, they disagree widely on these estimates.
ZVRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | -32% |
| Q3 2026 | $1.21 | +227% |
| Q2 2026 | $0.94 | +$1.25 |
| Q1 2026 | $2.01 | +$4.01 |
| Q4 2025 | $1.35 | +$3.69 |
| Q3 2025 | $0.37 | +$2.37 |
| Q2 2025 | -$0.31 | +$1.40 |
| Q1 2025 | -$2.00 | -$0.62 |
| Q4 2024 | -$2.34 | -$1.02 |
ZVRA earned $1.21 per share over the past year, about three times what it earned the year before.
ZVRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | +45% |
| Q2 2026 | $39.7M | +53% |
| Q1 2026 | $36.2M | +78% |
| Q4 2025 | $34.1M | +183% |
| Q3 2025 | $26.1M | +605% |
| Q2 2025 | $25.9M | +482% |
| Q1 2025 | $20.4M | +496% |
| Q4 2024 | $12M | -8.9% |
ZVRA's revenue has grown year over year for seven quarters in a row: $38M last quarter, up 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | +15 points |
| Q2 2026 | 42% | +317 points |
| Q1 2026 | 144% | +170 points |
| Q4 2025 | 27% | +155 points |
| Q3 2025 | 16% | +755 points |
| Q2 2025 | -274% | +260 points |
| Q1 2025 | -26% | +572 points |
| Q4 2024 | -128% | -17 points |
ZVRA's operating margin was 31% last quarter, up 15 points from the same quarter a year ago.
ZVRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +136% |
| Q2 2026 | $16.8M | +$20.6M |
| Q1 2026 | $6.1M | +$14.4M |
| Q4 2025 | $5.5M | +$21.8M |
| Q3 2025 | $4.2M | +$22.3M |
| Q2 2025 | -$3.8M | +$15.3M |
| Q1 2025 | -$8.3M | +$7.8M |
| Q4 2024 | -$16.3M | -$20K |
ZVRA's free cash flow has turned positive after six years mostly in the red: $38M over the past year.
ZVRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +396K shares |
| 1 year | +10% | +5.8M shares |
| 3 years | +78% | +27M shares |
| 5 years | +75% | +26.5M shares |
| Available history | +3231% | +59.9M shares |
ZVRA has 62M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.4M |
ZVRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q4 2021 | -14.1x | Net Cash |
| Q3 2021 | -17.3x | Net Cash |
| Q2 2021 | -15.3x | Net Cash |
| Q1 2021 | -14.1x | Net Cash |
ZVRA has more cash than debt.
ZVRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.9 | Neutral |
| Stochastic | 45.9 | Neutral |
ZVRA's weekly RSI is 51 (neutral) and its Stochastic is 46 (neutral).
ZVRA PE vs Healthcare Sector
| Metric | ZVRA | Sector median | Relative |
|---|---|---|---|
| PE | 9.2x | 26x | 64% below |
| PE % | 40 | 29 | 11 pts above |
ZVRA is trading at 9.2x earnings, a 64% discount to the Healthcare sector's median of 26x.
ZVRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.7 | 4.8% above |
| 20 week MA | $11.3 | 1.5% below |
| 50 week MA | $10.4 | 7.3% above |
| 100 week MA | $9.66 | 16% above |
| 200 week MA | $7.72 | 45% above |
ZVRA's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
ZVRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.69 | $11.5 | +72% |
| 2021 | $11.5 | $8.97 | -22% |
| 2022 | $8.97 | $4.29 | -52% |
| 2023 | $4.29 | $6.55 | +53% |
| 2024 | $6.55 | $8.39 | +28% |
| 2025 | $8.39 | $8.87 | +5.7% |
| 2026 YTD | $8.87 | $11.2 | +26% |
ZVRA has finished higher in four of the last six years, two of them by more than 50%. It's up 26% so far in 2026.